Cosmos Health Inc. (NASDAQ:COSM – Get Free Report) was the target of some unusual options trading on Friday. Investors bought 2,543 call options on the stock. This is an increase of approximately 337% compared to the typical volume of 582 call options.
Hedge Funds Weigh In On Cosmos Health
A hedge fund recently bought a new stake in Cosmos Health stock. BlackRock Inc. bought a new stake in Cosmos Health Inc. (NASDAQ:COSM – Free Report) during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 267,797 shares of the company’s stock, valued at approximately $49,000. BlackRock Inc. owned about 0.45% of Cosmos Health as of its most recent filing with the SEC. 12.61% of the stock is currently owned by hedge funds and other institutional investors.
Cosmos Health Price Performance
Shares of Cosmos Health stock traded up $0.01 during trading on Friday, hitting $0.30. 197,308 shares of the company’s stock traded hands, compared to its average volume of 4,100,915. Cosmos Health has a twelve month low of $0.16 and a twelve month high of $0.82. The company has a market cap of $30.59 million, a PE ratio of -0.47 and a beta of 4.73. The firm’s fifty day moving average price is $0.31 and its 200 day moving average price is $0.31. The company has a debt-to-equity ratio of 0.15, a current ratio of 1.05 and a quick ratio of 0.92.
Cosmos Health (NASDAQ:COSM – Get Free Report) last posted its earnings results on Tuesday, August 18th. The company reported ($0.10) EPS for the quarter, hitting the consensus estimate of ($0.10). The business had revenue of $19.32 million during the quarter, compared to the consensus estimate of $18.99 million. Cosmos Health had a negative return on equity of 56.88% and a negative net margin of 33.08%. Analysts forecast that Cosmos Health will post -0.15 earnings per share for the current year.
Analysts Set New Price Targets
Several research firms have commented on COSM. Weiss Ratings reissued a “sell (d-)” rating on shares of Cosmos Health in a research report on Wednesday, October 28th. Noble Financial started coverage on Cosmos Health in a research report on Monday, October 26th. They issued an “outperform” rating on the stock. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold”.
Read Our Latest Stock Report on COSM
Cosmos Health Company Profile
Cosmos Health Inc is a healthcare group that develops, manufactures and distributes pharmaceutical, nutraceutical and healthcare products. Its portfolio includes branded dietary supplements, vitamins and wellness products, as well as pharmaceutical products and medical devices distributed through retail, wholesale and online channels.
The company markets its nutraceutical products under the Sky Premium Life brand, which offers supplements and other health and wellness products. Cosmos Health also has manufacturing and product-development activities through Cana Laboratories, a Greece-based pharmaceutical manufacturer that produces pharmaceutical and healthcare products for its own portfolio and third parties.
Founded in 2009 and formerly known as Cosmos Holdings, the company adopted the Cosmos Health name in 2022.
See Also
- Five stocks we like better than Cosmos Health
- Arista Networks Cashes In on the AI Infrastructure Buildout
- Powering Up: Freeport-McMoRan’s $4.5B Copper Expansion
- 3 Dividend ETFs Offer Different Ways to Navigate the Post-Election Sell-Off
- Riot’s $28B Lease Shows Why Location and Contracts Matter in AI
Receive News & Ratings for Cosmos Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cosmos Health and related companies with MarketBeat.com's FREE daily email newsletter.
